• 1
    Weissmann B, Meyer K. The structure of hyalobiuronic and of hyaluronic acid from umbilical cord. J Am Chem Soc 1954; 76: 17537.
  • 2
    Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992; 6: 2397404.
  • 3
    Scott JE, Cummings C, Brass A, Chen Y. Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowing-electron microscopy and computer simulation: hyaluronan is a very efficient network-forming polymer. Biochem J 1991; 274: 699705.
  • 4
    Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993; 7: 123341.
  • 5
    Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Bio 2006; 85: 699715.
  • 6
    Edwards JC, Morris V. Joint physiology: relevant to the rheumatologist? Br J Rheumatol 1998; 37: 1215.
  • 7
    Sanchez-Lazaro J, Diaz-Gallego L. The clinical impact of physical-chemical characteristics of different hyaluronic acids as a treatment for osteoarthritis. Int J Biol Macromol 2006; 38: 3001.
  • 8
    Lee HG, Cowman MK. An agarose gel electrophoretic method for analysis of hyaluronan molecular weight distribution. Anal Biochem 1994; 219: 27887.
  • 9
    Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985; 44: 81722.
  • 10
    Flugge LA, Miller-Deist LA, Petillo PA. Towards a molecular understanding of arthritis. Chem Biol 1999; 6: R15766.
  • 11
    Dahl IM, Husby G. Hyaluronic acid production in vitro by synovial lining cells from normal and rheumatoid joints. Ann Rheum Dis 1985; 44: 64757.
  • 12
    Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1: 97103.
  • 13
    Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995; 3: 21325.
  • 14
    Marshall KW. Intra-articular hyaluronan therapy. Curr Opin Rheumatol 2000; 12: 46874.
  • 15
    Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274: 2508592.
  • 16
    Recklies AD, White C, Melching L, Roughley PJ. Differential regulation and expression of hyaluronan synthases in human articular chondrocytes, synovial cells and osteosarcoma cells. Biochem J 2001; 354: 1724.
  • 17
    Stuhlmeier KM, Pollaschek C. Glucocorticoids inhibit induced and non-induced mRNA accumulation of genes encoding hyaluronan synthases (HAS): hydrocortisone inhibits HAS1 activation by blocking the p38 mitogen-activated protein kinase signalling pathway. Rheumatology (Oxford) 2004; 43: 1649.
  • 18
    Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23: 138591.
  • 19
    Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998; 6 Suppl A: 1421.
  • 20
    Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998; 6 Suppl A: 316.
  • 21
    Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage 1998; 6 Suppl A: 2530.
  • 22
    Malaise M, Marcolongo R, Uebelhart D, Vignon E. Efficacy and tolerability of 800 mg oral chondroitin 4&6 sulfate in the treatment of knee osteoarthritis: a randomised, double-blind, multicentre study versus placebo. Litera Rheumatologica 1999; 24: 3142.
  • 23
    Volpi N. The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 11927.
  • 24
    McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 146975.
  • 25
    Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795808.
  • 26
    Bassleer CT, Combal JP, Bougaret S, Malaise M. Effects of chondroitin sulfate and interleukin-1β on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1998; 6: 196204.
  • 27
    Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E2 in articular cartilage explants. Osteoarthritis Cartilage 2005; 13: 38794.
  • 28
    Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res 2005; 66: 18706.
  • 29
    Legendre F, Bauge C, Roche R, Saurel AS, Pujol JP. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1β-stimulated chondrocytes—study in hypoxic alginate bead cultures. Osteoarthritis Cartilage 2008; 16: 10514.
  • 30
    McCarty MF. Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis. Med Hypotheses 1998; 50: 50710.
  • 31
    Delpech B, Bertrand P, Maingonnat C, Girard N, Chauzy C. Enzyme-linked hyaluronectin: a unique reagent for hyaluronan assay and tissue location and for hyaluronidase activity detection. Anal Biochem 1995; 229: 3541.
  • 32
    Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 1569.
  • 33
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2math image method. Methods 2001; 25: 4028.
  • 34
    Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003; 116: 186373.
  • 35
    Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 2003; 278: 4580110.
  • 36
    Hascall VC, Majors AK, de la Motte CA, Evanko SP, Wang A, Drazba JA, et al. Intracellular hyaluronan: a new frontier for inflammation? Biochim Biophys Acta 2004; 1673: 312.
  • 37
    Nishida Y, Knudson CB, Knudson K. Osteogenic protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis Cartilage 2004; 12: 37482.
  • 38
    Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 52839.
  • 39
    Wilkinson TS, Bressler SL, Evanko SP, Braun KR, Wight TN. Overexpression of hyaluronan synthases alters vascular smooth muscle cell phenotype and promotes monocyte adhesion. J Cell Physiol 2006; 206: 37885.
  • 40
    Mummert ME. Immunologic roles of hyaluronan. Immunol Res 2005; 31: 189206.
  • 41
    Yung S, Thomas GJ, Davies M. Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro. Kidney Int 2000; 58: 195362.
  • 42
    Yamada Y, Itano N, Hata KI, Ueda M, Kimata K. Differential regulation by IL-1β and EGF of expression of three different hyaluronan synthases in oral mucosal epithelial cells and fibroblasts and dermal fibroblasts: quantitative analysis using real-time RT-PCR. J Invest Dermatol 2004; 122: 6319.
  • 43
    Nishikawa H, Mori I, Umemoto J. Influences of sulfated glycosaminoglycans on biosynthesis of hyaluronic acid in rabbit knee synovial membrane. Arch Biochem Biophys 1985; 240: 14653.
  • 44
    Nishikawa H, Mori I, Umemoto J. Glycosaminoglycan polysulfate-induced stimulation of hyaluronic acid synthesis in rabbit knee synovial membrane: involvement of binding protein and calcium ion. Arch Biochem Biophys 1988; 266: 2019.
  • 45
    Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 130313.
  • 46
    Prehm P. Mechanism, localization, and inhibition of hyaluronate synthesis. In: KuettnerK, editor. Articular cartilage biochemistry. New York: Raven Press; 1986. p. 597600.
  • 47
    Kawakami M, Suzuki K, Matsuki Y, Ishizuka T, Hidaka T, Konishi T, et al. Hyaluronan production in human rheumatoid fibroblastic synovial lining cells is increased by interleukin 1β but inhibited by transforming growth factor β1. Ann Rheum Dis 1998; 57: 6025.
  • 48
    Stuhlmeier KM, Pollaschek C. Differential effect of transforming growth factor β (TGF-β) on the genes encoding hyaluronan synthases and utilization of the p38 MAPK pathway in TGF-β-induced hyaluronan synthase 1 activation. J Biol Chem 2004; 279: 875360.
  • 49
    Spicer AP, McDonald JA. Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. J Biol Chem 1998; 273: 192332.
  • 50
    Ross GT, Marsh JM, Roback DW. Uridine diphosphate glucose dehydrogenase in rheumatoid synovial cells in culture. J Rheumatol 1981; 8: 7105.
  • 51
    Pitsillides AA, Blake SM. Uridine diphosphoglucose dehydrogenase activity in synovial lining cells in the experimental antigen induced model of rheumatoid arthritis: an indication of synovial lining cell function. Ann Rheum Dis 1992; 51: 9925.
  • 52
    Pitsillides AA, Wilkinson LS, Mehdizadeh S, Bayliss MT, Edwards JC. Uridine diphosphoglucose dehydrogenase activity in normal and rheumatoid synovium: the description of a specialized synovial lining cell. Int J Exp Path 1993; 74: 2734.
  • 53
    Stuhlmeier KM, Pollaschek C. Adenovirus-mediated gene transfer of mutated IκB kinase and IκBα reveal NF-κB-dependent as well as NF-κB-independent pathways of HAS1 activation. J Biol Chem 2005; 280: 4276673.
  • 54
    Goentzel BJ, Weigel PH, Steinberg RA. Recombinant human hyaluronan synthase 3 is phosphorylated in mammalian cells. Biochem J 2006; 396: 34754.
  • 55
    Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung 1995; 45: 91825.
  • 56
    Ronca G, Conte A. Metabolic fate of partially depolymerized shark chondroitin sulfate in man. Int J Clin Pharm Res 1993; 13: 2734.
  • 57
    Lualdi P. Bioavailability of oral chondroitin sulfate. Rheumatol Int 1993; 13: 3943.